The Medicines Company (MDCO) Receives Average Rating of “Buy” from Brokerages

Shares of The Medicines Company (NASDAQ:MDCO) have earned an average rating of “Buy” from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $51.40.

A number of equities analysts have recently weighed in on the company. Oppenheimer set a $50.00 price target on The Medicines and gave the stock a “hold” rating in a report on Thursday, October 26th. Citigroup raised The Medicines from a “sell” rating to an “outperform” rating in a report on Thursday, November 30th. BidaskClub raised The Medicines from a “strong sell” rating to a “sell” rating in a report on Thursday. Jefferies Group reiterated a “buy” rating and issued a $54.00 target price on shares of The Medicines in a research note on Thursday, October 26th. Finally, ValuEngine upgraded The Medicines from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st.

In other The Medicines news, Director Alexander J. Denner bought 170,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was purchased at an average cost of $30.03 per share, for a total transaction of $5,105,100.00. Following the completion of the purchase, the director now owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Fredric N. Eshelman purchased 200,000 shares of the stock in a transaction on Friday, December 8th. The shares were purchased at an average cost of $26.56 per share, with a total value of $5,312,000.00. Following the transaction, the insider now owns 1,028,383 shares of the company’s stock, valued at approximately $27,313,852.48. The disclosure for this purchase can be found here. Corporate insiders own 8.22% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new stake in The Medicines during the third quarter valued at about $171,000. SG Americas Securities LLC purchased a new stake in The Medicines during the third quarter valued at about $198,000. Bluefin Trading LLC purchased a new stake in The Medicines during the second quarter valued at about $214,000. Ameritas Investment Partners Inc. boosted its position in shares of The Medicines by 4.2% in the second quarter. Ameritas Investment Partners Inc. now owns 6,058 shares of the company’s stock worth $230,000 after buying an additional 243 shares during the period. Finally, HighTower Advisors LLC boosted its position in shares of The Medicines by 16.2% in the second quarter. HighTower Advisors LLC now owns 6,754 shares of the company’s stock worth $258,000 after buying an additional 941 shares during the period.

The Medicines (MDCO) traded up $0.02 during midday trading on Friday, hitting $33.60. The stock had a trading volume of 2,332,688 shares, compared to its average volume of 1,645,017. The Medicines has a 12 month low of $24.45 and a 12 month high of $55.95. The firm has a market capitalization of $2,447.89, a PE ratio of -3.68 and a beta of 0.71. The company has a debt-to-equity ratio of 3.42, a quick ratio of 1.79 and a current ratio of 2.31.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The company had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $26.06 million. During the same period in the previous year, the firm posted ($0.64) earnings per share. The business’s revenue for the quarter was down 55.1% compared to the same quarter last year. analysts forecast that The Medicines will post -8.86 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “The Medicines Company (MDCO) Receives Average Rating of “Buy” from Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/27/the-medicines-company-mdco-receives-average-rating-of-buy-from-brokerages.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply